New York, NY -- (SBWIRE) -- 01/09/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: DARA Biosciences Inc (NASDAQ:DARA), Exelixis, Inc (NASDAQ:EXEL), Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX), Magnum Hunter Resources Corp (NYSE:MHR)
DARA Biosciences Inc (NASDAQ:DARA) showed a volume of 2.94 million shares by the end of last trade whereas the average volume of the stock remained 944,417.00 shares. The stock opened the session at $0.63 but then moved to $0.570. At that price, the stock showed a negative performance of -10.25%. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959. Its KRN5500 is a non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer.
Will DARA Get Buyers Even After The Recent Rally? Find Out Here
Exelixis, Inc (NASDAQ:EXEL) opened the session at $6.86 and closed the session at $7.00. The stock showed a positive performance of 2.26% in previous trading session. Traded with volume of 2.92 million shares in the prior session and the average volume of the stock remained 1.67 million shares. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET,
For How Long EXEL will fight for Profitability? Read This Trend Analysis report
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) opened the session at $2.22 and closed the session at $2.14. The stock showed a positive performance of 5.94% in previous trading session. Traded with volume of 2.88 million shares in the prior session and the average volume of the stock remained 1.02 million shares. The beta of the stock remained 0.46. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115,
Why Should Investors Buy CPRX After The Recent Gain? Just Go Here and Find Out
Magnum Hunter Resources Corp (NYSE:MHR) the stock advanced 0.83% and finished the session at $7.28. Traded with volume of 2.80 million shares in the prior session and the average volume of the stock remained 3.87 million shares. The beta of the stock remained 1.50. Magnum Hunter Resources Corporation (Magnum Hunter) is an independent oil and gas company engaged in the exploration for and the exploitation, acquisition, development and production of crude oil, natural gas and natural gas liquids, primarily in the states of West Virginia, Ohio, Texas, Kentucky and North Dakota and in Saskatchewan, Canada. The Company is also engaged in midstream operations, including the gathering of natural gas through its ownership and operation of a gas gathering system in West Virginia and Ohio, named as its Eureka Hunter Pipeline System.
Will MHR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)